Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I

In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

The overlooked nutrition risk of Ozempic and Wegovy

Popular weight-loss drugs like Ozempic and Wegovy can dramatically curb appetite, but experts warn many users are flying blind when it comes to nutrition. New research suggests people taking these medications may not be getting enough guidance on protein, vitamins, and overall diet quality, increasing the risk of muscle loss and nutrient deficiencies.

Weight Loss: What I Wish I’d Known Before Taking Compounded Semaglutide

Semaglutide erased the constant mental chatter about food that had ruled her life, but along with it went her awareness of basic needs.

Writer Kristen Reed shares her weight loss journey with compounded semaglutide. Photography courtesy of Kristen Reed

Health and wellness touch everyone’s life differently. This is one person’s story. The views and opinions expressed are those of the speaker and do not necessarily reflect the views or positions of Healthline Media.